DNTHDianthus Therapeutics, Inc.
$82.35+124% 1Y
$82.35
$32.9252 weeks$115.67
DNTH in its own filings
DNTH's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
172
Events found in the filings · across 655 filings · the record starts in 2018
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 10-Q
- Record starts
- Apr 24, 2018
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Change in certifying accountant2 occurrences
- 2023-10-25
- Delisting notice / listing-rule failurehistorical
- 2023-02-02
- SEC comment-letter activity32 occurrences
- 2026-01-29
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W initiated in June ‘26, with top-line results anticipated in 2H’28.Earnings release · press release
- Mar 26, 2026On March 26, 2026, Dianthus Therapeutics, Inc. (the "Company") posted an updated corporate presentation (the "Presentation") on the investor relations section of its website.Other event · Form 8-K
- Mar 12, 2026On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named …Material agreement entered · Form 8-K
- Mar 9, 2026On March 9, 2026, the Company made publicly available a data presentation announcing early GO decision following interim responder analysis in Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (the “Presentation”) on the investor relations section of its website.Earnings release · Form 8-K
- Nov 3, 2025On November 3, 2025, Dianthus Therapeutics, Inc. posted an updated corporate presentation (the "Presentation") on the investor relations section of its website.Other event · Form 8-K
- Oct 16, 2025Ltd. On October 16, 2025, Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Nanjing Leads Biolabs Co. Ltd. (“Leads”), pursuant to which Leads granted the Company a royalty-bearing, exclusive license outside of Greater China to …Material agreement entered · Form 8-K
- Sep 11, 2025On September 9, 2025, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., and Stifel, Nicolaus & Company, Incorporated, as the representatives of the underwriters named therein (the …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks